English | 简体中文 | 繁體中文 | 한국어
Share:
NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
YASTEST NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers

Nouvelle image.JPG

NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS

Paris, France and Cambridge, Massachusetts, USA, January 11, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy.

The collaboration with Providence Cancer Institute, located at the Robert W. Franz Cancer Center in Portland, Ore., one of the world's leading oncological research centers, will provide essential preclinical data on the ability of NBTXR3 activated by radiotherapy to induce an antitumoral immune response. This is an in-depth study into the early immunologic mechanisms, triggered by nanoparticles activated by radiotherapy compared to radiotherapy alone, and their impact on tumor control, survival and metastasis spreading.

Marka R. Crittenden, M.D., Ph.D., radiation oncologist and director of Translational Radiation Research at the Robert W. Franz Cancer Center will lead the program. "Promising pre-clinical data suggests that nanoparticles combined with radiotherapy enhance tumor-specific immune responses and lead to an abscopal response, priming a patient's immune system to attack cancer cells outside of the radiotherapy target area," she said. "Furthermore, we are absolutely delighted to partner with Nanobiotix to advance our research on this phenomenon and the role NBTXR3 can play in immuno-oncology."

The collaboration between Providence and Nanobiotix will take place over the course of one year, and will evaluate the use of NBTXR3 activated by radiotherapy in pancreatic cancer models (in vitro and in vivo). Pancreatic cancer is a disease with a substantial unmet medical need, poor response to standard of care and is the third leading cause of cancer mortality in both men and women in the United State. Pancreatic cancers have a non-immunogenic tumor microenvironnement, known as "cold tumors", and often have a poor response rate to immunotherapies.

The results of this joint program will enable the potential to explore future use of NBTXR3 in immuno-oncology as well as its potential to control metastatic disease.

In parallel, the Company has received the approval of its Investigational New Drug (IND) and will launch its first clinical trial combining NBTXR3 with immune checkpoint inhibitors in the U.S. with a multi-arm trial targeting a sub-population of advanced lung cancer patients and head and neck cancer patients. Nanobiotix's immuno-oncology combination program opens the door to new developments, potential new indications and important value creation opportunities.

***
             
About Providence Cancer Institute

Providence Cancer Institute, a part of Providence Health & Services, offers the latest in cancer services, including diagnostic, treatment, prevention, education, support and internationally-renowned research. Located within the Robert W. Franz Cancer Center in Portland, Ore., Providence Cancer Institute is home to the Earle A. Chiles Research Institute, a world-class research facility for cancer immunotherapy, a specialized field of study focused on triggering the immune system to fight cancer. Visit www.providenceoregon.org/cancer to learn more.

About NBTXR3

NBTXR3 is an injectable aqueous suspension of hafnium oxide nanoparticles designed as an innovative therapeutic agent for the treatment of solid tumors, currently in clinical development by Nanobiotix.

Once injected intratumorally, NBTXR3 can deposit high energy within tumors only when activated by an ionizing radiation source, notably radiotherapy. Upon activation, the high energy radiation is physically designed to kill the tumor cells by triggering DNA damage and cell destruction and improve clinical outcomes.

Promising results indicate that NBTXR3 activity could be applicable across solid tumors triggering immunogenic cell death, leading to an immune response, reinforcing a local and potentially systemic effect, and contributing to transform "cold" tumors into "hot" tumors. NBTXR3's major characteristics are represented by a high degree of biocompatibility, one single administration before and during the whole therapy and the ability to fit into current standards of radiotherapy care.

NBTXR3 entered clinical development in 2011 in a Phase I/II with patients suffering from advanced soft tissue sarcoma of the extremities and is currently in the final stages of its subsequent phase II/III. In parallel, it is currently being tested in numerous Phase I/II clinical trials with patients suffering from locally advanced squamous cell carcinoma of the oral cavity or oropharynx (head and neck), liver cancer (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.

About NANOBIOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region.

The Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company's Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.

Contact

Nanobiotix
 

Sarah Gaubert
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
[email protected] /
[email protected]

 
 

Noël Kurdi
Director, Investor Relations
+1 (646) 241-4400
[email protected] / [email protected]
Media relations
Nanobiotix
France - Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
[email protected]
   

United States - RooneyPartners
Marion Janic
+1 (212) 223-4017
[email protected]
 

Providence Cancer Institute
Jean Powell Marks
+1 (503) 215-6433
[email protected]

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NANOBIOTIX via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
INGREDION INVESTS $140 MILLION TO ACCELERATE GROWTH IN PLANT-BASED PROTEINS  
Dec 13, 2018 22:29 ET
Pöyry PLC: Statement of the Board of Directors of Pöyry Plc Regarding the Voluntary Public Cash Tender Offer by ÅF AB (publ)  
Dec 13, 2018 17:00 ET
Pöyry PLC: Notice of change in ownership in compliance with Chapter 9, Section 10 of the Securities Market Act  
Dec 13, 2018 16:20 ET
Scandinavian Tobacco Group A/S: Notification and Public Disclosure of Transaction by Person Discharging Managerial Responsibilities  
Dec 13, 2018 16:00 ET
INGREDION INVESTS $140 MILLION TO ACCELERATE GROWTH IN PLANT-BASED PROTEINS  
Dec 13, 2018 15:04 ET
XPO Logistics Finds that 86% of US Consumers Consider Return Policies when Shopping Online  
Dec 13, 2018 14:30 ET
CLX Communications AB (publ): CLX Communications appoints new CFO  
Dec 12, 2018 15:59 ET
Lubrizol Announces Strategic Alliance with Vidalia Denim for Sustainably-Produced Denim Featuring X4zol(TM)-J Stretch Fibers:  
Dec 11, 2018 06:59 ET
Eastman Board Increases Dividend for Ninth Consecutive Year  
Dec 7, 2018 05:29 ET
AIR Worldwide Estimates Insured Losses from Camp Wildfire Will Be Between USD 6 Billion and USD 9 Billion  
Dec 6, 2018 22:59 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: